



Opinion_

Who pays compensation if a COVID-19 vaccine has rare side-effects?

20 October 2020

What does Australia's latest indemnity deal mean in practice?

Share 

To encourage people to receive COVID-19 vaccines for the benefit of the entire community, we need compensation schemes to be in place if there is a rare but serious side-effect, writes Associate Professor Nicholas Wood.

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK

Although details are unclear, it appears the government would foot the bill for compensation if a member of the public wins legal action against the drug company.

This is in contrast to [25 other countries \[https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233334\]](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233334) with no-fault compensation schemes for rare vaccine side-effects.

Here's the little we know about Australia's latest indemnity deal and what we could be doing better.

What do we know about Australia's new deal?

The deal relates to [two vaccines \[https://theconversation.com/putting-our-money-on-two-covid-vaccines-is-better-than-one-why-australias-latest-vaccine-deal-makes-sense-145693\]](https://theconversation.com/putting-our-money-on-two-covid-vaccines-is-better-than-one-why-australias-latest-vaccine-deal-makes-sense-145693) the government had previously announced it would supply, should clinical trials prove successful.

These are the University of Oxford vaccine, from AstraZeneca, and the University of Queensland vaccine, from Seqirus (part of CSL).

However, it is not entirely clear what this indemnity deal means in practice. The budget papers [say \[https://budget.gov.au/2020-21/content/bp1/download/bp1_bs9_w.pdf\]](https://budget.gov.au/2020-21/content/bp1/download/bp1_bs9_w.pdf) the government will cover: '*certain liabilities that could result from the use of the vaccine.*'

The government [considers \[https://thenewdaily.com.au/news/2020/10/09/government-grants-covid-19/\]](https://thenewdaily.com.au/news/2020/10/09/government-grants-covid-19/) further details "commercial in confidence".

For instance, we don't know how serious or disabling a side-effect would have to be to qualify or whether there is any cap on the amount of compensation.

We also don't know what would happen if there were errors involved, or contaminants introduced, while manufacturing the vaccine. These would still be the company's liability, but it may be hard to determine where boundaries lie.

How unusual is this?

This deal is not entirely new or unexpected. The government has [provided some indemnity \[https://budget.gov.au/2020-21/content/bp1/download/bp1_bs9_w.pdf\]](https://budget.gov.au/2020-21/content/bp1/download/bp1_bs9_w.pdf) to pharmaceutical companies that make vaccines against smallpox and influenza.

The governments of many other countries have also agreed to indemnify COVID-19 vaccine manufacturers, [including \[https://www.rt.com/news/496801-pharma-not-accountable-vaccine-effect/%20and%20https://www.reuters.com/article/us-health-coronavirus-vaccines-liability/covid-19-era-highlights-a-block-hole-compensation-fund-for-pandemic-vaccine-injuries-idUSKBN25U1501\]](https://www.rt.com/news/496801-pharma-not-accountable-vaccine-effect/%20and%20https://www.reuters.com/article/us-health-coronavirus-vaccines-liability/covid-19-era-highlights-a-block-hole-compensation-fund-for-pandemic-vaccine-injuries-idUSKBN25U1501) governments in

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK




RAND Corporation ✓

@RANDCorporation



How might concerns over compensation affect the public's uptake of a #COVID19 vaccine when/if one becomes available?

And what might policymakers do to address such concerns?



COVID-19 Vaccinations: Liability and Compensation Considerations for P...

Vaccine development is only one part of the challenge in creating an immunization campaign to stop the pandemic. Once a safe and effective...

rand.org

12:53 AM · Oct 12, 2020



The manufacturers [believe \[https://www.europeanpharmaceuticalreview.com/news/125517/astrazeneca-receives-protection-from-covid-19-vaccine-liability-claims-report-says/\]](https://www.europeanpharmaceuticalreview.com/news/125517/astrazeneca-receives-protection-from-covid-19-vaccine-liability-claims-report-says/) that as the use of their vaccine is for the benefit of society, they should not be held financially accountable for any consequences from a vaccine reaction.

So what does this mean for the public?

If a person in Australia believes they have been injured by a vaccine, including future COVID-19 vaccines, they will

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK

However this is not ideal. The person still has to engage with the legal system, which is both costly and complex, and there's no guarantee of success.

Compensation may not even be possible via our legal system. That's because in most cases, it will be difficult to show in court a serious side-effect was due to a fault in the vaccine composition or negligence in the way it was administered.

So in Australia, people with a vaccine injury, either COVID-19 or other vaccine, will likely bear the costs of their injury by themselves, and seek treatment by our publicly-funded or private health systems.

The National Disability Insurance Scheme helps fund therapies for people with a permanent and significant disability but [does not cover](https://www1.racgp.org.au/ajgp/coronavirus/australia-needs-a-vaccine-injury-compensation-sche) temporary vaccine-related injuries.

Participants in COVID-19 vaccine clinical trials [can be compensated](https://medicinesaustralia.com.au/policy/clinical-trials/indemity-and-compensation-guidelines/) for temporary and permanent vaccine injuries.

What's happening overseas?

In the US, people with a rare but serious reaction to a COVID-19 vaccine will be able to access a [special compensation scheme](https://www.hrsa.gov/cicp). This is designed to provide compensation for the use of COVID-19 pandemic medications and vaccines.

However, applicants only have one year from the date they had the vaccine or medicine to request benefits.

The US already has [a vaccine compensation scheme](https://www.hrsa.gov/vaccine-compensation/index.html) for vaccines other than COVID-19. This is an example of a [no-fault](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233334) compensation scheme. These compensate for specific vaccine reactions, without having to go to court to prove the vaccine manufacturer is liable.

Australia, in contrast to 25 countries including the US, UK and New Zealand, [does not have](https://www1.racgp.org.au/ajgp/coronavirus/australia-needs-a-vaccine-injury-compensation-sche) a no-fault vaccine compensation scheme, and does not have the equivalent of the US COVID-19 vaccine compensation scheme.

How would a no-fault system work?

There are numerous benefits to a no-fault vaccine compensation system. These include simplified access to compensation, and avoiding a lengthy, costly and complex encounter with the legal system, with no guarantee of

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK

 **Juan Gérvas**
@JuanGrvas 

25 countries have a no-fault compensation programmes for #vaccine injuries. Japan, Germany, Canada, Vietnam, France, South Korea, USA, Austria, Italy, New Zealand, etc. 25 países tienen un sistema no judicial de daños por #vacunas De EEUU a Francia, etc.



Global landscape analysis of no-fault compensation ...
To update the landscape analysis of vaccine injuries no-fault compensation programmes, we conducted ...
journals.plos.org

4:13 AM · Aug 5, 2020 

 5  1  Share this Tweet

Finland and Sweden fund their programs via insurance payments from pharmaceutical companies marketing their products there.

The [New Zealand scheme \[https://www.acc.co.nz/\]](https://www.acc.co.nz/) includes compensation for vaccine-related injuries, as well as for accidents and treatment injuries. This is funded through a combination of general taxation, and levies collected from employee earnings, businesses, vehicle licensing and fuel.

However, compensation awarded via such no-fault schemes is usually lower than you would receive after a successful liability lawsuit.

Where to next?

To encourage people to receive COVID-19 vaccines for the benefit of the entire community, we need compensation schemes to be in place if there is a rare but serious side-effect.

Should options to increase vaccine uptake include mandates or penalties – such as employment or travel restrictions if not vaccinated – this would make a no-fault vaccine compensation scheme even more essential.

Although it is important manufacturers receive indemnity for “certain liabilities”, we still need to look after our

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK

This article was first published on [The Conversation \[https://theconversation.com/who-pays-compensation-if-a-covid-19-vaccine-has-rare-side-effects-heres-the-little-we-know-about-australias-new-deal-147846\]](https://theconversation.com/who-pays-compensation-if-a-covid-19-vaccine-has-rare-side-effects-heres-the-little-we-know-about-australias-new-deal-147846). It was written by [Associate Professor Nicholas Wood \[https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/nicholas-wood.html\]](https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/nicholas-wood.html), Faculty of Medicine and Health at the University of Sydney.

Kobi Print

Media & PR Adviser - Health

Mobile

[+61 481 012 729](tel:+61481012729)

Email

kobi.print@sydney.edu.au

Related articles

News_

06 October 2020

News_

24 September 2020

Opinion

07 Octo



'No jab, no pay' raises catch-up vaccination rates

University of Sydney to advance COVID-19 DNA vaccine to human trials

Do Tv vacci not th

The University of Sydney is testing a novel

The key

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).



and for Indigenous Australians, finds new research led by Sydney researchers.



THE UNIVERSITY OF
SYDNEY

Leadership for good starts here

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK

Media

News

Find an expert

Media contacts

Student links

How to log in to University systems

Key dates

Class timetables

Policies

About us

Our rankings

Faculties and schools

Centres and institutes

Campus locations

Connect

Contact us

Find a staff member

Careers at Sydney

Event calendar

Emergencies and personal safety

Member of



Follow

ABN: 15 211 513 464

CRICOS Number: 00026A

Disclaimer

Privacy

Accessibility

Website feedback

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK

We use cookies to improve your experience on our site and to show you personalised content. For more information about how we use cookies, please read our [Privacy Statement](#).

OK